Showing 2642 results
- Media Release /New findings show Cosentyx® (secukinumab) 300 mg single dose autoinjector (the UnoReady® pen) resulted in superior efficacy vs placebo1 Patient satisfaction with 300 mg autoinjector…
- Pulse Update /
- Media Release /Data analysis shows that preventing the symptoms of CSU (achieving complete control) improves overall health-related quality of life (HRQoL); including sleep and work productivity, among other…
- Media Release /Acquisition underscores Novartis commitment to using optogenetics-based therapies to restore vision to patients with advanced blindness Novartis gains one pre-clinical optogenetic AAV gene therapy…
- Media Release /Basel, June 2, 2020 — Novartis today announced that it has received notice from the US Food and Drug Administration (FDA) that the agency has extended its review of the Supplemental Biologics…
- Media Release /More than half of patients with BRAF-mutated advanced melanoma taking Tafinlar + Mekinist were alive and free of a relapse at 5-years1 Study conclusions are drawn from the largest dataset and…
- Media Release /Piqray (alpelisib) in combination with fulvestrant will become first and only targeted treatment for advanced breast cancer patients whose tumors harbor a PIK3CA mutation in Europe Phase III…
- Media Release /Novartis presented a total of 34 abstracts at the Congress of the European Academy of Neurology (EAN), emphasizing its strong multiple sclerosis (MS) portfolio with 20 abstractsLong-term efficacy…
- Media Release /New MONALEESA-7 (M7) and MONALEESA-3 (M3) subgroup analysis to be presented during ASCO20 Virtual Scientific Program Subgroup analysis shows Kisqali plus endocrine therapy extended life…
- Story /
People with breast cancer need better medicines that help reduce the risk and anxiety of it returning.
Pagination
- ‹ Previous page
- 1
- …
- 229
- 230
- 231
- 232
- 233
- 234
- 235
- …
- 265
- › Next page